Healthcare / BiotechnologyMCE
$3.06
-0.08 (-2.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.7M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$242M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2.2%
↓Gross Margin
N/A
•Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
5.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-3.1M · FCF $-15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-3.1M | $-3.1M | $-3.7M | $-3.7M | $-4.5M |
| EBITDA | $-5.7M | $-5.7M | $-4.3M | $-4.5M | $-5.7M |
| EPS | -0.04 | -0.04 | -0.06 | -0.06 | -0.08 |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.13 | 0.17 | 0.24 |
| Cash Flow | |||||
| Free Cash Flow | $-15.7M | $-15.7M | $-14.0M | $-16.7M | $-17.3M |
| Returns | |||||
| ROE | -2.2% | -2.2% | -4.1% | -4.1% | -5.8% |
| Valuation | |||||
| P/B | 1.72 | 1.72 | 1.06 | 1.49 | 2.03 |
| Growth & Yield | |||||
| EPS Growth | 31.3% | 31.3% | 5.6% | 24.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → -0.04
Residual
+5.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.